Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

August 02, 2023

Paolo Corradini, MD, of Italy’s Istituto Nazionale Dei Tumori, discusses findings from the CART-SIE Real Life Italian Study, which compared treatment outcomes for patients with relapsed or refractory primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL), all of whom received axicabtagene ciloleucel. The trial showed that those with PMBCL had superior survival outcomes than did those with DLBCL.

Related Content